Medical research has established that a high Body Mass Index (BMI) adversely impacts one’s risk for obesity, diabetes, cardiovascular, and cancer. However, researchers in South Australia at Flinders University may have discovered the exception to the rule: for those on a regimen of atezolizumab, a common immunotherapy treatment for Non-Small Cell Lung Cancer (NSCLC), a high BMI is associated with higher probability outcomes of survival.
Published recently in JAMA Oncology in a report titled Association Between Body Mass Index (BMI) and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small-Cell Lung Cancer: Analysis of Atezolizumab Clinical Trials, the research team Down Under found the exact opposite to be true in certain situations when it comes to BMI.
Led by Ganessan Kichenadasse, MD, a medical oncology researcher at the Flinders Centre for Innovation Cancer, the findings are “interesting” and raise the consideration for further study inclusive of other anticancer drugs. More specifically, Kichenadasse noted the need to study possible links between BMI and related inflammation, which could point to a better understanding of the mech...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).